Superworth

Embecta price to free cash flow EMBC

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Nov 2, 2026
2.1×
4-year median
12.1×
Against its 4-year history
12th
percentile: 0 is its lowest day, 100 its highest
4-year range
0.9× to 95.5×
Peer median
12.3×

Embecta's price to free cash flow is 2.1× as of Nov 2, 2026.

That is below its 4-year median of 12.1×, lower than on 88% of days in the last 4 years.

Over that time it ranged from 0.9× in Jun 2026 to 95.5× in Jul 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 12.3×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.1×0.9×4.1×
20253.9×3.8×59.9×
202460.5×23.6×95.5×
202326.3×3.4×26.3×
20223.7×3.7×4.0×

Against its peers

Companies in Medical - Instruments & Supplies nearest Embecta's size, closest first, today.

CompanyPrice to free cash flow
EMBCEmbecta2.1×
INFUInfuSystem12.0×
TCMDTactile Systems Technology19.3×
UTMDUtah Medical Products19.6×
PDEXPro DEX17.3×
MOVMovado10.0×
IRMDIradimed38.9×
IARTIntegra Lifesciences12.3×
BVSBioventus11.7×
STAAStaar Surgicaln/m
KEQUKewaunee Scientific8.9×
Peer median12.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Embecta

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.